France (FR)

Message Passing for a Bayesian Semi-Blind Approach to Cell-Free Massive MIMO (2022) Gholami R, Cottatellucci L, Slock D Conference contribution Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment (2022) Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, et al. Journal article Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study (2022) Hoertel N, Sánchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Abellán M, de la Muela P, et al. Journal article Rhodium-Based Metal-Organic Polyhedra Assemblies for Selective CO2Photoreduction (2022) Ghosh AC, Legrand A, Rajapaksha R, Craig GA, Sassoye C, Balázs G, Farrusseng D, et al. Journal article Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) (2022) Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, et al. Journal article 360º optoacoustic capsule endoscopy at 50 Hz for esophageal imaging (2022) Ali Z, Zakian C, Li Q, Gloriod J, Crozat S, Bouvet F, Pierre G, et al. Journal article Correction to: A new benchmark of soft X-ray transition energies of Ne, CO2, and SF6: paving a pathway towards ppm accuracy (The European Physical Journal D, (2022), 76, 3, (38), 10.1140/epjd/s10053-022-00355-0) (2022) Stierhof J, Kuehn S, Winter M, Micke P, Steinbruegge R, Shah C, Hell N, et al. Journal article, Erratum Neuroendocrine Tumor Treatments and Follow-up Disease Management: Comparative Perspective (US and Canada vs Global) (2022) Kolarova T, Hollander R, Mcdonnell M, Bouvier C, Pavel ME, Singh H, Howe J, et al. Conference contribution [Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study (2022) Singh S, Pavel ME, Kunz PL, De Herder W, Herrmann K, D'Amelio AM, Santoro P, et al. Conference contribution Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial (2022) Dromain C, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Capdevila J, et al. Conference contribution